Patents by Inventor Steven Tarran Jones

Steven Tarran Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8604172
    Abstract: Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: December 10, 2013
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Patent number: 8222373
    Abstract: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: July 17, 2012
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Patent number: 8067549
    Abstract: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: November 29, 2011
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Patent number: 8025877
    Abstract: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: September 27, 2011
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Williams
  • Patent number: 8026342
    Abstract: The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: September 27, 2011
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Patent number: 7981416
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: July 19, 2011
    Assignees: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
  • Patent number: 7956173
    Abstract: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: June 7, 2011
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Patent number: 7829674
    Abstract: The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: November 9, 2010
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Publication number: 20090263386
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.
    Type: Application
    Filed: March 18, 2009
    Publication date: October 22, 2009
    Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
  • Patent number: 7524498
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: April 28, 2009
    Assignees: CureTech Ltd., Mor-Research Application Ltd.
    Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
  • Publication number: 20090099339
    Abstract: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.
    Type: Application
    Filed: July 9, 2008
    Publication date: April 16, 2009
    Applicant: ImClone Systems Incorporated
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • Patent number: 7479543
    Abstract: A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRS, and mouse H chain CDRs of a monoclonal antibody to the IL-6R. Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: January 20, 2009
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Tsuchiya, Koh Sato, Mary Margaret Bendig, Steven Tarran Jones, Jose William Saldanha
  • Patent number: 7332582
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: February 19, 2008
    Assignees: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
  • Patent number: 7060808
    Abstract: A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: June 13, 2006
    Assignee: ImClone Systems Incorporated
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • Publication number: 20050142635
    Abstract: A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRS, and mouse H chain CDRs of a monoclonal antibody to the IL-6R. Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.
    Type: Application
    Filed: May 4, 2004
    Publication date: June 30, 2005
    Inventors: Masayuki Tsuchiya, Koh Sato, Mary Margaret Bendig, Steven Tarran Jones, Jose Saldanha
  • Publication number: 20040006212
    Abstract: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.
    Type: Application
    Filed: February 25, 2003
    Publication date: January 8, 2004
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • Publication number: 20030224001
    Abstract: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.
    Type: Application
    Filed: February 25, 2003
    Publication date: December 4, 2003
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • Patent number: 5817790
    Abstract: A reshaped human antibody to the human IL-6R, comprising:(A) an L chain comprising,(1) a human L chain C region, and(2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a monoclonal antibody to the IL-6 receptor (IL-6R); and(B) an H chain comprising,(1) a human H chain C region, and(2) an H chain V region comprising human H chain FRs, and mouse H chain CDRs of a monoclonal antibody to the IL-6R.Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: October 6, 1998
    Assignee: Chugai Seiyaku Kabushiki
    Inventors: Masayuki Tsuchiya, Koh Sato, Mary Margaret Bendig, Steven Tarran Jones, Jose William Saldanha
  • Patent number: 5795965
    Abstract: A reshaped human antibody to the human IL-6R, comprising:(A) an L chain comprising,(1) a human L chain C region, and(2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRS) of a momoclonal antibody to the IL-6 receptor (IL-6R); and(B) an H chain comprising,(1) a human H chain C region, and(2) an H chain V region comprising human H chain FRs, and mouse H chain CDRs of a monoclonal antibody to the IL-6R.Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.
    Type: Grant
    Filed: December 20, 1993
    Date of Patent: August 18, 1998
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Tsuchiya, Koh Sato, Mary Margaret Bendig, Steven Tarran Jones, Jose William Saldanha